PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: South Korea

PE Guidelines
Pharmaceutical Economic Evaluation Guidelines (January 2006)
PDF in Korean

PE Guidelines Source:
Health Insurance Review & Assessment Service

Additional Information:
PE Guideline Key Features in Progress

Last Webpage Update: Tuesday, May 17, 2011

PE Guidelines Key Features:

Key Features:  
Title and year of the documentPharmaceutical Economic Evaluation Guidelines (January 2006) 
Affiliation of authors 
Purpose of the document 
Standard reporting format included 
Target audience of funding/ author's interests 
Target population 
Subgroup analysis 
Choice of comparator 
Time horizon 
Assumptions required 
Preferred analytical technique 
Costs to be included 
Source of costs 
Systematic review of evidences 
Preference for effectiveness over efficacy 
Preferred outcome measure 
Preferred method to derive utility 
Equity issues stated 
Discounting costs 
Discounting outcomes 
Sensitivity analysis-parameters and range 
Sensitivity analysis-methods 
Presenting results 
Incremental analysis 
Total costs vs effectiveness (cost/effectiveness ratio) 
Portability of results (Generalizability) 
Financial impact analysis 
Mandatory or recommended or voluntary 

Country Selection Page | PE Guidelines Index Page